Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Super-enhancer analysis reveals subtypes in AML and MDS

Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA
Super-enhancer analysis reveals subtypes  in AML and MDS ( Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA )
12 Jun 2016

Novel therapies for older patients with AML and MDS

Prof Naval Daver - MD Anderson Cancer Center, Houston, United States
Novel therapies for older patients with AML and MDS ( Prof Naval Daver - MD Anderson Cancer Center, Houston, United States )
12 Jun 2016

Better screening programmes needed for haematological malignancies such as leukaemia

Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany
Better screening programmes needed for haematological malignancies such as leukaemia ( Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany )
12 Jun 2016

Karyotyping a CLL subset with ibrutinib susceptibility

Dr Jeffrey Jones - Ohio State University, Columbus, USA
Karyotyping a CLL subset with ibrutinib susceptibility ( Dr Jeffrey Jones - Ohio State University, Columbus, USA )
12 Jun 2016

Chemo-genomic interrogation reveals JAK sensitive subgroup in AML

Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML ( Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada )
12 Jun 2016

Targeted genome editing in haematopoeitic stem cells

Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
Targeted genome editing in haematopoeitic stem cells ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016

A microRNA driver of B-cell leukaemia

Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
A microRNA driver of B-cell leukaemia ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016

Risk adapted therapy for acute myeloid leukaemia

Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain
Risk adapted therapy for acute myeloid leukaemia ( Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain )
11 Jun 2016

Evaluation of ibrutinib in treatment of CLL with 17p deletion

Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA
Evaluation of ibrutinib in treatment of CLL with 17p deletion ( Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA )
10 Jun 2016

An overview of MCL from EHA 2016

Professor Simon Rule and Professor Steven Le Gouill
An overview of MCL from EHA 2016 ( Professor Simon Rule and Professor Steven Le Gouill )
10 Jun 2016

The value and strategy for incorporating biosimilars Into clinical practice

Dr Francisco Esteva - New York University, New York, USA
The value and strategy for incorporating biosimilars Into clinical practice ( Dr Francisco Esteva - New York University, New York, USA )
7 Jun 2016

Checkpoint inhibitor therapy benefits advanced bladder cancer patients

Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA
Checkpoint inhibitor therapy benefits advanced bladder cancer patients ( Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA )
7 Jun 2016